Loading patent…
OwnerJoseph M. Fayad, Jerome Schentaginventors
Estimating the term…
The invention provides pharmaceutical compositions, methods for the treatment of, and related diagnostics and computer-implementable systems that relate to, the treatment of a variety of metabolic syndromes, including hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states. In an additional aspect of the invention, compositions and methods of treatment are calibrated to the ileal brake response to surgical intervention e.g. Roux-en-Y gastric bypass (RYGB)) as both activate the ileal brake, which acts in the gastrointestinal tract and the liver of a mammal to control metabolic syndrome manifestations and thereby reverse or ameliorate the cardiovascular damage (atherosclerosis, hypertension, lipid accumulation, and the like) resulting from progression of metabolic syndrome. The net benefit is the potential to treat all of the common manifestations of metabolic syndrome, including Type 2 diabetes and obesity, with one medicament, which contains glucose as an activation agent for the ileal brake. The ileal brake is the controller for progression of metabolic syndrome, and both RYGB surgery and the oral formulation act beneficially on the metabolic syndrome manifestations via this pathway. Disclosed as well are combination medicaments that act synergistically on the ileal brake and the manifestations of metabolic syndrome. In other aspects, the invention provides ileal brake hormone releasing compositions, methods of treatment, diagnostics, and related systems useful in selective control of appetite, stabilizing blood glucose and insulin levels, and treating gastrointestinal disorders in a similar manner to RYGB surgery, but having at least 20% of the potency to stimulate the hormonal response of the ileal brake of humans.
A method of treating the manifestations of metabolic syndrome in a patient or subject comprising orally administering an effective amount of an enteric coated, ileum hormone stimulating amount of an ileal brake hormone releasing substance wherein said manifestations of metabolic syndrome include one or more of the following 1) a selective modulation of appetite in said patient with metabolic syndrome and obesity;
3-36. (canceled)
A method of treating a subject who suffers from non-alcoholic fatty liver disease (NAFLD) or fatty liver disease associated with hepatitis or other liver injury associated with fatty liver or inflammation, said method comprising once-daily administration to the subject of a delayed and/or controlled release oral dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises an enterically-coated, ileum hormone-stimulating amount of an ileal brake hormone releasing substance, wherein said microparticles release the ileal brake hormone substance at pH values specific to the coating, and a preferred ileal brake releasing hormone substance is a blending of microparticles with pH release at 6.8, 7.0, 7.2 and 7.5 and mixtures thereof in therapeutically active proportions of microparticles are claimed as well as each microparticle alone in compositions containing said ileal brake hormone releasing substance, such that the majority of the ileal brake hormone releasing substance is released from the dosing form when the dosage form reaches the subject's ileum.
38-49. (canceled)
A method of treating at least one of the manifestations of metabolic syndrome using a delayed or controlled release ileal brake hormone releasing medicament in a subject for a period of at least about twenty-four hours, wherein said manifestation are selected from the group consisting of weight loss, decrease in appetite, decrease in insulin resistance, decrease in triglycerides, beneficial immunomodulation, decrease in glucose and including satiety and selective appetite modulation, said treatment further having an effect on metabolic syndrome manifestations in said patient or subject lasting 6 months with continued once-daily administration to the subject, wherein the dosage form is administered at a time of around four to around ten hours prior to the subject's next intended meal, and wherein the dosage form comprises an active drug in immediate release form which treats one or more of the manifestations of metabolic syndrome in combination dosing formulation with an ileum hormone-stimulating amount of an ileal brake hormone releasing substance said dosage form releasing the majority of the ileal brake hormone releasing substance in vivo upon reaching the subject's ileum, wherein said substance activates or re-activate the L-cells of the ileum, thereby producing all of the chemical and physiological characteristics of an activated ileal brake in a manner similar to RYGB surgery.
52-57. (canceled)
A method of diagnosing whether a subject suffers from an abnormally hypo responsive ileal hormone release disorder, the method comprising:
A method of diagnosing whether a subject suffers from an obesity-related or abnormally responsive ileal hormone release disorder, the method comprising
60-61. (canceled)
A method of treating a gastrointestinal disease or disorder in a patient in need thereof comprising administering to said patient an effective amount of a controlled release composition comprising an ileum hormone stimulating ileal brake hormone releasing substance which releases at least 50% by weight of said ileal brake hormone releasing substance in the ileum of said patient wherein said gastrointestinal disease or disorder selected from the group consisting of atrophic gastritis, post chemotherapy disorder, intestinal motility disorder (gut dysmotility), mild reflux, chronic pancreatitis, malnutrition, malabsorption, voluntary or involuntary long term starvation, post infectious syndrome, short bowel syndrome, irritable bowel, malabsorption, diarrheal states, post chemotherapy gastrointestinal disorder, post infectious syndrome, radiation enteritis, celiac disease, fatty liver disease, cirrhosis, radiation, inflammatory bowel disease and Crohn's disease.
A method of treating a disease or disorder selected from the group consisting of metabolic syndrome manifestations, pre-diabetic symptoms, noninsulin dependent diabetes mellitus, glucose intolerance or insulin resistance or a disease state or condition which occurs secondary to said disease or disorder comprising administering to said patient or subject an effective amount of microparticulate formed ileal brake hormone releasing substance, said microparticles releasing the ileal brake hormone substance at pH values specific to the coating.
64-68. (canceled)
A method of treating a patient or subject to decrease fatty liver, increase the size of beta cells in the pancreas or increase the size of absorptive villae of the small bowel of said patient or subject comprising administering to said patient or subject an effective amount of an ileal brake hormone releasing substance and releasing at least 50% of the ileal brake hormone releasing substance in said composition in the ileum of said patient or subject, whereupon the compositional formulation may either activate or re-activate the L-cells of the ileum and thereby produce all of the chemical and physiological characteristics of an activated ileal brake in a manner similar to RYGB surgery.
70-74. (canceled)
A method of treatment comprising administering a ileal brake hormone releasing substance composition containing GRAS ingredients for treating noninsulin dependent diabetes mellitus, pre-diabetic symptoms, and insulin resistance, the ileal brake hormone releasing substance composition containing an effective amount of an ileal brake hormone releasing substance, optionally combined with one or more of Alfalfa leaf, chlorella algae, chlorophyllin and barley grass juice concentrate, and further formulated into a delayed release form adapted to release the ileal brake hormone releasing substance in the lower gut or ileum, whereupon the compositional formulation may either activate or re-activate the L-cells of the ileum and thereby produce all of the chemical and physiological characteristics of an activated ileal brake in a manner similar to RYGB surgery.
76-117. (canceled)
A method of treating, inhibiting or reducing the likelihood of a fatty liver disease in a patient said method comprising administering an effective amount of an ileum hormone-stimulating amount of an ileal brake hormone releasing substance which releases the majority of the ileal brake hormone releasing substance in vivo upon reaching the subject's ileum as otherwise described herein, wherein the compositional formulation may activate or re-activate the L-cells of the ileum and thereby produce chemical and physiological characteristics of an activated ileal brake in a manner similar to RYGB surgery.
120-121. (canceled)
A method of treatment comprising administering to a subject in need thereof an ileum hormone-stimulating amount of an ileal brake hormone releasing substance which releases in vivo substantially in the subject's ileum, wherein (1) the subject suffers from, or is at risk of developing, a metabolic syndrome selected from the group of metabolic syndrome manifestations consisting of hyperlipidemia, weight gain, obesity, insulin resistance, hypertension, atherosclerosis, fatty liver diseases and certain chronic inflammatory states (2) optionally, prior to or concurrent with administration, a level one or more of the subject's metabolic syndrome biomarkers is measured and the ileal brake hormone releasing substance or dosage of ileal brake hormone releasing substance is selected based on the biomarker level, and (3) wherein the ileal brake hormone releasing substance comprises at least one microencapsulated sugar, lipid, or amino acid and activates the subject's ileal brake.
123-191. (canceled)
A method of stimulating cellular level regeneration of target organs and tissues by administering an effective amount of a ileal brake hormone releasing substance (an oral mimetic of RYGB surgery) to a human patient in need thereof, wherein the substance can be used alone or in combination to treat any condition that is improved by RYGB surgery and the associated cellular level regeneration of target organs and tissues.
193-199. (canceled)
Dependencies are inferred from the claim text.